Sucampo Pharmaceuticals — Q1 2016 Earnings Presentation
26 slides from Sucampo Pharmaceuticals's earnings presentation, May 4, 2016
Slide 1: First Quarter 2016 Corporate Update and Financial Results
€ een. First Quarter 2016 Corporate Update and Financial Results May 4, 2016
Slide 2: Introductions and Forward-Looking Statements
Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs
Slide 3: Agenda
Agenda $ sucampo Introductions and Forward-Looking Statements Corporate Update Pipeline Update Financial Update Closing Remarks Silvia Taylor Peter Greenleaf Peter Kiener, D. Phil Andrew Smith Peter Greenleaf
Slide 4: Forward Looking Statement
Forward Looking Statement $ sucampo ‘Sucampo Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. ‘These statements are based on management's current expectations and involve risks and uncer
Slide 5: Q1 2016 - Peter Greenleaf, Chairman and CEO
Q1 2016 Corporate Update Peter Greenleaf, Chairman and CEO
Slide 6: Strong Financial Performance and Continued Progress Against Our Strategic Objectives
Strong Financial Performance and Continued Progress Against * Our Strategic Objectives 2 SUCAMPO 1. Continue to deliver outstanding financial performance 2. Continue to prioritize and progress our pipeline 3. Continue to transform our company for sustained mid- and long-term growth
Slide 7: Solid Financial Results
Solid Financial Results $ sucamPo REVENUE * Q1 overall revenue grew 60% YoY to $47.2M — Increased demand for AMITIZA in U.S. and Japan — Inclusion of the results of RTU + Q1 revenue grew 18% excluding $12.4M RTU-related revenue EARNINGS + Adjusted Net Income grew 40% YoY to $9.0M + Adjusted EPS grew
Slide 8: Strong U.S. AMITIZA Performance
Strong U.S. AMITIZA Performance $ sucampo * Takeda AMITIZA net sales for royalty calc. purposes — Q1 grew 4.8% YoY to $91.7M — Royalty revenue grew 5.1% YoY to $16.5M + AMITIZA prescriptions — Q1IMS: ~360,000 TRx, increased 5% YoY — 2015 exceptionally strong year - 5% remains consistent/slightly hig
Slide 9: Strong Growth Trends
Strong Growth Trends $ 1. Continued robust demand for AMITIZA in U.S. - Unique mechanism of action — First and only brand to be approved for three types of chronic constipation 2. Takeda continues to drive strong brand promotion — New marketing campaign geared toward patient education and awareness
Slide 10: Robust Japan AMITIZA Performance
Robust Japan AMITIZA Performance $ sucampo + Sucampo revenue — Q1 grew 31% YoY to $14.5M + Volume-driven growth + Mylan remains focused on: - Sales efforts to high-volume/high-decile physicians —- Driving switches from non-Rx options to AMITIZA + AMITIZA only branded Rx for CC in Japan — Continues t
Slide 11: Reaffirming 2016 Guidance
Reaffirming 2016 Guidance $ sucampo + Total revenue: $195.0 million to $205.0 million + Adjusted net income: $45.0 million to $50.0 million + Adjusted EPS: $0.97 to $1.07 + Adjusted EBITDA: $100.0 million to $105.0 million — Guidance excludes amortization of acquired intangibles of approximately $17
Slide 12: Pipeline Progress: Upcoming Milestones
Pipeline Progress: Upcoming Milestones $ sucampo_ VAP-1 (RTU-1096) AMITIZA (lubiprostone) AMITIZA. (lubiprostone) AMITIZA (lubiprostone) AMITIZA (lubiprostone) CPP-1X/sulindac combination product Cobiprostone AMITIZA (lubiprostone) Cobiprostone AMITIZA (lubiprostone) Event Top-line data from Phase 1
Slide 13: Transform Business Through Business Development
Transform Business Through Business Development $ sucampo + Exclusive option for a Phase 3 program in familial adenomatous polyposis (FAP) with Cancer Prevention Pharmaceuticals + Enter into rare and orphan disease space + Harnesses our expertise in gastroenterology + R-Tech Ueno integration progres
Slide 14: Pipeline Update
Pipeline Update Peter Kiener, D.Phil, CSO
Slide 15: Product Pipeline Overview
Product Pipeline Overview $ SUCAMPO Development Stage Program First indication hag AMITIZA cic2 Pediatric functional constipation Pa 2016 2017 Lubiprostone Pediatric functional constipation = 2018 (1); 2019 (1); Microparticle Formulation CC? (1); adutt cic (2) 2017 (2) 2018 (2) Bate Poly-amines Fami
Slide 16: Lifecycle Management Programs for AMITIZA
Lifecycle Management Programs for AMITIZA $ + Pediatric Functional Constipation (6-17 years) Recently completed enrollmentin P3 study Uses current formulation Data expected 2H16 Plan to file sNDA2H16 + Alternate Formulation Expectto initiate P3 study in adult patients with CIC 2H16 Expect data 1H17
Slide 17: Cobiprostone
Cobiprostone $ sucamPo_ + NERD/sGERD — Phase 2a data did not support advancement of cobiprostone in this indication — Data showed significant benefit in some secondary measures — Affirmed cobiprostone is well-tolerated * Consistent with P1 studies * Oral Mucositis — P2a study ongoing - Futility anal
Slide 18: Additional Development Stage Programs
Additional Development Stage Programs RTU — 1096 VAP-1 Inhibitor + Top-line results expected from Phase 1 MAD 1H16 CPP-1X/sulindac Combo: Exclusive Option for Phase 3 Asset in FAP * Significant opportunity — Phase 3 asset — Orphan indication for familial adenomatous polyposis (FAP) * Clinical develo
Slide 19: Financial Update
Financial Update Andrew Smith, CFO
Slide 20: Q1 Total Revenue
Q1 Total Revenue $ sucampo “ey mz 350 4 ss ‘$Milion g 150 } 100 7 | & 50 00 12015, R-Tech inckision —AMITIZAUS Royalty = AMITIZA Japan other qi 2016
Slide 21: Adjusted EBITDA
Adjusted EBITDA $ sucampo 250 150 | $ Million 100 } 50 00 a1 2015, A-Tech inclusion Revenue contribution 212016
Slide 22: Debt Position
Debt Position | item =| As 0f 3/31/16 As of 12/31/15 Cash, Cash $157.0M ($6.5M) $163.5M Equivalents and Restricted Cash Total Debt ($235.7M) $16.7M ($252.4M) Net Debt ($78.7M) $10.2M ($88.9M)
Slide 23: Reaffirming 2016 Guidance
Reaffirming 2016 Guidance $ sucampo + Total revenue: $195.0 million to $205.0 million + Adjusted net income: $45.0 million to $50.0 million + Adjusted EPS: $0.97 to $1.07 + Adjusted EBITDA: $100.0 million to $105.0 million — Guidance excludes amortization of acquired intangibles of approximately $17
Slide 24: Closing Remarks
Closing Remarks Peter Greenleaf, Chairman and CEO
Slide 25: 2016 Areas of Focus
2016 Areas of Focus $ sucampo 1. Deliver outstanding financial performance: driven by top and bottom-line growth 2. Advance pipeline programs 3. Evaluate additional opportunities for accelerated /sustainable mid-to- long- te
Slide 26: Q&A Session
Q&A Session
Sucampo Pharmaceuticals — Q1 2016 Earnings Presentation on 6ix